ClinicalTrials.gg
Active, not recruitingNCT06773962Updated Apr 23, 2026

A Phase 2a Multicenter Clinical Trial of TB006 in Participants With Parkinson's Disease

A Phase 2 interventional study of TB006 and Placebo in Parkinson's Disease (PD), sponsored by TrueBinding, Inc.. Active, not recruiting at 14 sites in United States. Open to participants aged 50 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-04-23.

Sponsored by TrueBinding, Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
62
Allocation
Randomized
Ages
50 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,649 studies in Parkinson Disease with a site in United States — 304 open to participants now, 386 under way, 7 of them phase 3. Parkinson Disease · United States.

Planned enrollment
406th of 1,256
62 · median 36
Started
2025
with 77 others
Phase 2
234 of 1,649
25 open now
Primary completion
2026-11
later than 93 of 383 live
Registered
1,496th of 1,649
by date

Among the 1,649 studies in Parkinson Disease with a site in United States, this one is the 406th largest by planned enrollment of the 1,256 interventional ones that give a count, is one of 78 that started in 2025, is one of 234 in phase 2, reaches primary completion later than 93 of the 383 other live ones, and was the 1,496th registered.

Parkinson Disease

4,578 studies on the registry are indexed under Parkinson Disease; 1,085 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

304 of the 1,649 studies in Parkinson Disease with a site in United States are open now. Recruiting first, the newest first:

299 more — sign in →

All 304 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 748 Parkinson Disease studies recruiting now, 311 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 50 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,649 studies in Parkinson Disease with a site in United States, or all of them as a file.
02

Study summary

The primary objectives of this study are to assess the efficacy of TB006 in improving motor function and to assess the safety of TB006 in participants with Parkinson's Disease (PD).

03

Conditions studied

  • Parkinson's Disease (PD)

Browse trials for

Keywords

  • PD
  • TB006
  • Monoclonal Antibody
  • Parkinson's Disease
04

Who can participate

Ages eligible
50 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants voluntarily agree to participate in this study and sign an Institutional Review Board (IRB)-approved form (ICF) prior to performing any of the screening procedures.

    Parkinson's Disease Related Criteria:

  2. Diagnosis of Parkinson's disease (PD) with motor symptom improvement from levodopa, if applicable.
  3. Less than 5 years from the initial PD diagnosis, at the time of ICF.
  4. Early-stage PD, with mild symptoms based on standard clinical staging in OFF state.
  5. Participants who are on immediate-release levodopa-carbidopa/benserazide.

    Other Health Related Criteria

  6. No active cancer, unless in remission for ≥10 years without ongoing treatment, except fully removed basal cell carcinoma.
  7. Free of significant health issues that might interfere with study participation.

    Other Criteria/Social Circumstances

  8. Negative screening for illegal drugs (excluding cannabis), with willingness to abstain during the study and avoid cannabis or alcohol effects during visits.

Exclusion criteria

Exclusion Criteria:

Parkinsons's Disease Related Criteria

  1. History of sudden, unexpected PD medication OFF episodes.
  2. Severe motor complications or disabling symptoms that may impact study involvement.

    Other Health Related Criteria

  3. Any condition or health concern deemed a safety risk or likely to interfere with study results.
  4. Severe psychiatric disorders, including psychosis or substance addiction.
  5. Allergies or sensitivities to specific study-related treatments or substances.
  6. Any prior history of a severe infusion reaction.

    Other Criteria/Social Circumstances

  7. Pregnancy, breastfeeding, or plans for pregnancy or ova donation during or shortly after the study.
  8. Recent use of drugs or therapeutic antibodies.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
62 participants (estimated)

Study arms

  • Experimental
    TB006

    Participants will receive TB006 via intravenous (IV) infusion.

    Drug: TB006

  • Placebo comparator
    Placebo

    Participants will receive placebo via IV infusion.

    Drug: Placebo

Interventions

  • DrugTB006

    IV infusion.

  • DrugPlacebo

    IV infusion.

06

What researchers measure

Primary outcomes

  1. Change from Baseline in Parkinson's Disease Rating Scale Score

    Time frame: Baseline to 28 weeks

  2. Number of Participants Experiencing Adverse Events

    Time frame: 28 weeks

  3. Number of Participants Experiencing Serious Adverse Events

    Time frame: 28 weeks

Secondary outcomes

  1. Change from Baseline in Parkinson's Disease Rating Scale Sub-score

    Time frame: Baseline to 28 weeks

  2. Change from Baseline in Patient Perceived Severity of Disease

    Time frame: Baseline to 28 weeks

  3. Change from Baseline in Clinician Perceived Severity of Disease

    Time frame: Baseline to 28 weeks

07

Study locations

14 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2025 (actual). Primary completion is estimated for Nov 2026, 20 months after the start.

Of 97 industry-sponsored phase 2 interventional studies under Parkinson Disease, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 33. This study's planned 20 months is close to that.

Counting every sponsor, half of 202 studies reached it within 28 months; a quarter within 16 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 8, 2025
First posted
Jan 14, 2025
StartActual
Mar 20, 2025
Primary completionEst.
Nov 28, 2026
CompletionEst.
Nov 28, 2026
Last update
Apr 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06773962
Lead sponsor
TrueBinding, Inc.
Responsible party
Sponsor
First posted
Jan 14, 2025
Start date
Mar 20, 2025
Primary completion
Nov 28, 2026 (estimated)
Completion
Nov 28, 2026 (estimated)
Last update
Apr 23, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: TB006

Start the discussion